Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone

Undine Schubert, Janine Schmid, Susann Lehmann, Xian Y. Zhang, Henning Morawietz, Norman L Block, Waldemar Kanczkowski, Andrew V Schally, Stefan R. Bornstein, Barbara Ludwig

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Here, we evaluate an alternative approach of preconditioning pancreatic islets before transplantation using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet viability and function, and we explore the adrenal gland as an alternative transplantation site for islet engraftment. The endocrine microenvironment of the adrenal represents a promising nichewith the unique advantages of exceptional high oxygen tension and local antiinflammatory and immunosuppressive properties. GHRH agonists have been shown to promote islet graft survival and function, which may help to reduce the islet mass necessary to reverse diabetes. In the present study, themost potent GHRH agonist MR403 was tested on insulinoma cells, isolated rat islets, and adrenal β-cell cocultures in vitro. GHRH receptor is expressed on both adrenal cells and islets. MR403 caused a significant increase in cell viability and proliferation and revealed an antiapoptotic effect on insulinoma cells. Viability of rat islets was increased after treatment with the agonist and in coculture with adrenal cells. Rat islets were transplanted into diabetic mice to the intraadrenal transplant site and compared with the classical transplants underneath the kidney capsule. Graft function and integration were tested by metabolic follow-up and immunohistochemical staining of intraadrenal grafts. A rapid decrease occurred in blood glucose levels in both models, and all animals reached normoglycemiawithin the first days after transplantation. Our studies demonstrated that the adrenal may be an attractive site for islet transplantation and that GHRH analogs might allow reduction of the islet mass needed to reverse a diabetic status.

Original languageEnglish
Pages (from-to)2288-2293
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number6
DOIs
StatePublished - Feb 5 2013

Fingerprint

Growth Hormone-Releasing Hormone
Islets of Langerhans Transplantation
Adrenal Glands
Transplants
Insulinoma
Coculture Techniques
Islets of Langerhans
Graft Survival
Immunosuppressive Agents
Capsules
Blood Glucose
Cell Survival
Anti-Inflammatory Agents
Animal Models
Transplantation
Cell Proliferation
Staining and Labeling
Oxygen
Kidney
Therapeutics

Keywords

  • β-Cell replacement
  • Regenerative therapy
  • Type 1 diabetes mellitus

ASJC Scopus subject areas

  • General

Cite this

Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone. / Schubert, Undine; Schmid, Janine; Lehmann, Susann; Zhang, Xian Y.; Morawietz, Henning; Block, Norman L; Kanczkowski, Waldemar; Schally, Andrew V; Bornstein, Stefan R.; Ludwig, Barbara.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 6, 05.02.2013, p. 2288-2293.

Research output: Contribution to journalArticle

Schubert, Undine ; Schmid, Janine ; Lehmann, Susann ; Zhang, Xian Y. ; Morawietz, Henning ; Block, Norman L ; Kanczkowski, Waldemar ; Schally, Andrew V ; Bornstein, Stefan R. ; Ludwig, Barbara. / Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 6. pp. 2288-2293.
@article{747a2ae7ed1546eb9f9e4a8d6fd8ea3d,
title = "Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone",
abstract = "Here, we evaluate an alternative approach of preconditioning pancreatic islets before transplantation using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet viability and function, and we explore the adrenal gland as an alternative transplantation site for islet engraftment. The endocrine microenvironment of the adrenal represents a promising nichewith the unique advantages of exceptional high oxygen tension and local antiinflammatory and immunosuppressive properties. GHRH agonists have been shown to promote islet graft survival and function, which may help to reduce the islet mass necessary to reverse diabetes. In the present study, themost potent GHRH agonist MR403 was tested on insulinoma cells, isolated rat islets, and adrenal β-cell cocultures in vitro. GHRH receptor is expressed on both adrenal cells and islets. MR403 caused a significant increase in cell viability and proliferation and revealed an antiapoptotic effect on insulinoma cells. Viability of rat islets was increased after treatment with the agonist and in coculture with adrenal cells. Rat islets were transplanted into diabetic mice to the intraadrenal transplant site and compared with the classical transplants underneath the kidney capsule. Graft function and integration were tested by metabolic follow-up and immunohistochemical staining of intraadrenal grafts. A rapid decrease occurred in blood glucose levels in both models, and all animals reached normoglycemiawithin the first days after transplantation. Our studies demonstrated that the adrenal may be an attractive site for islet transplantation and that GHRH analogs might allow reduction of the islet mass needed to reverse a diabetic status.",
keywords = "β-Cell replacement, Regenerative therapy, Type 1 diabetes mellitus",
author = "Undine Schubert and Janine Schmid and Susann Lehmann and Zhang, {Xian Y.} and Henning Morawietz and Block, {Norman L} and Waldemar Kanczkowski and Schally, {Andrew V} and Bornstein, {Stefan R.} and Barbara Ludwig",
year = "2013",
month = "2",
day = "5",
doi = "10.1073/pnas.1221505110",
language = "English",
volume = "110",
pages = "2288--2293",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "6",

}

TY - JOUR

T1 - Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone

AU - Schubert, Undine

AU - Schmid, Janine

AU - Lehmann, Susann

AU - Zhang, Xian Y.

AU - Morawietz, Henning

AU - Block, Norman L

AU - Kanczkowski, Waldemar

AU - Schally, Andrew V

AU - Bornstein, Stefan R.

AU - Ludwig, Barbara

PY - 2013/2/5

Y1 - 2013/2/5

N2 - Here, we evaluate an alternative approach of preconditioning pancreatic islets before transplantation using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet viability and function, and we explore the adrenal gland as an alternative transplantation site for islet engraftment. The endocrine microenvironment of the adrenal represents a promising nichewith the unique advantages of exceptional high oxygen tension and local antiinflammatory and immunosuppressive properties. GHRH agonists have been shown to promote islet graft survival and function, which may help to reduce the islet mass necessary to reverse diabetes. In the present study, themost potent GHRH agonist MR403 was tested on insulinoma cells, isolated rat islets, and adrenal β-cell cocultures in vitro. GHRH receptor is expressed on both adrenal cells and islets. MR403 caused a significant increase in cell viability and proliferation and revealed an antiapoptotic effect on insulinoma cells. Viability of rat islets was increased after treatment with the agonist and in coculture with adrenal cells. Rat islets were transplanted into diabetic mice to the intraadrenal transplant site and compared with the classical transplants underneath the kidney capsule. Graft function and integration were tested by metabolic follow-up and immunohistochemical staining of intraadrenal grafts. A rapid decrease occurred in blood glucose levels in both models, and all animals reached normoglycemiawithin the first days after transplantation. Our studies demonstrated that the adrenal may be an attractive site for islet transplantation and that GHRH analogs might allow reduction of the islet mass needed to reverse a diabetic status.

AB - Here, we evaluate an alternative approach of preconditioning pancreatic islets before transplantation using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet viability and function, and we explore the adrenal gland as an alternative transplantation site for islet engraftment. The endocrine microenvironment of the adrenal represents a promising nichewith the unique advantages of exceptional high oxygen tension and local antiinflammatory and immunosuppressive properties. GHRH agonists have been shown to promote islet graft survival and function, which may help to reduce the islet mass necessary to reverse diabetes. In the present study, themost potent GHRH agonist MR403 was tested on insulinoma cells, isolated rat islets, and adrenal β-cell cocultures in vitro. GHRH receptor is expressed on both adrenal cells and islets. MR403 caused a significant increase in cell viability and proliferation and revealed an antiapoptotic effect on insulinoma cells. Viability of rat islets was increased after treatment with the agonist and in coculture with adrenal cells. Rat islets were transplanted into diabetic mice to the intraadrenal transplant site and compared with the classical transplants underneath the kidney capsule. Graft function and integration were tested by metabolic follow-up and immunohistochemical staining of intraadrenal grafts. A rapid decrease occurred in blood glucose levels in both models, and all animals reached normoglycemiawithin the first days after transplantation. Our studies demonstrated that the adrenal may be an attractive site for islet transplantation and that GHRH analogs might allow reduction of the islet mass needed to reverse a diabetic status.

KW - β-Cell replacement

KW - Regenerative therapy

KW - Type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84873455727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873455727&partnerID=8YFLogxK

U2 - 10.1073/pnas.1221505110

DO - 10.1073/pnas.1221505110

M3 - Article

C2 - 23345449

AN - SCOPUS:84873455727

VL - 110

SP - 2288

EP - 2293

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 6

ER -